Ryo Sasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ryo Sasaki has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Toru Yamashita
Department of Neurology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
11 shared publications Mami Takemoto
Department of Neurology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
8 shared publications- Emi Nomura
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan
6 shared publications Nozomi Hishikawa
Department of Neurology Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan
6 shared publicationsRyuta Morihara
Department of Neurology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
6 shared publications- Koh Tadokoro
Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
5 shared publications
Latest Publications
- 15 June 2026
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 14 (5) , 439-441
Opercular Myoclonic‐Anarthric Status Epilepticus Evolving From Focal Epilepsy
- 15 June 2026
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 14 (5) , 439-441
Opercular Myoclonic‐Anarthric Status Epilepticus Evolving From Focal Epilepsy
- 5 March 2026
- Published by Wiley in Neurology and Clinical Neuroscience
Monitoring CSF MOG Antibody in a Relapsing Case of MOGAD With Isolated CSF Positivity
Myelin oligodendrocyte glycoprotein antibody‐associated disease presents with diverse clinical courses, and some patients experience frequent relapses. Although various immunotherapies have been employed, optimal long‐term management strategies remain unclear. We report the case of a 37‐year‐old woman diagnosed with myelin oligodendrocyte glycoprotein antibody‐associated disease. Myelin oligodendrocyte glycoprotein antibody was detected only in cerebrospinal fluid. The patient was primarily treated with steroids; however, she experienced recurrent encephalitis with multifocal brain lesions. A brain biopsy showed no evidence of neoplastic changes. High‐dose intravenous immunoglobulin maintenance therapy and azathioprine were initiated, resulting in clinical stabilization and conversion to cerebrospinal fluid myelin oligodendrocyte glycoprotein antibody negativity. Over 1.5 years of follow‐up, no relapse occurred and cerebrospinal myelin oligodendrocyte glycoprotein antibody negativity was retained. This case highlights the potential utility of monitoring cerebrospinal fluid myelin oligodendrocyte glycoprotein antibody as biomarkers for treatment response in myelin oligodendrocyte glycoprotein antibody‐associated disease, especially in seronegative cases.
- 5 March 2026
- Published by Wiley in Neurology and Clinical Neuroscience
Monitoring CSF MOG Antibody in a Relapsing Case of MOGAD With Isolated CSF Positivity
Myelin oligodendrocyte glycoprotein antibody‐associated disease presents with diverse clinical courses, and some patients experience frequent relapses. Although various immunotherapies have been employed, optimal long‐term management strategies remain unclear. We report the case of a 37‐year‐old woman diagnosed with myelin oligodendrocyte glycoprotein antibody‐associated disease. Myelin oligodendrocyte glycoprotein antibody was detected only in cerebrospinal fluid. The patient was primarily treated with steroids; however, she experienced recurrent encephalitis with multifocal brain lesions. A brain biopsy showed no evidence of neoplastic changes. High‐dose intravenous immunoglobulin maintenance therapy and azathioprine were initiated, resulting in clinical stabilization and conversion to cerebrospinal fluid myelin oligodendrocyte glycoprotein antibody negativity. Over 1.5 years of follow‐up, no relapse occurred and cerebrospinal myelin oligodendrocyte glycoprotein antibody negativity was retained. This case highlights the potential utility of monitoring cerebrospinal fluid myelin oligodendrocyte glycoprotein antibody as biomarkers for treatment response in myelin oligodendrocyte glycoprotein antibody‐associated disease, especially in seronegative cases.
- 7 December 2025
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 14 (1) , 96-97
Reversible Multiple Cerebral Arterial Stenosis With a Streptococcus intermedius Intracranial Abscess
- 7 December 2025
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 14 (1) , 96-97
Reversible Multiple Cerebral Arterial Stenosis With a Streptococcus intermedius Intracranial Abscess
- 11 July 2025
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 13 (5) , 369-371
A Case of Autoimmune Glial Fibrillary Acid Protein Astrocytopathy Presenting an Irreversible Lesion in the Corpus Callosum
A 22‐year‐old female patient displayed fevers, headaches, and disturbed consciousness. A brain MRI demonstrated hyperintensity in the splenium of the corpus callosum with diffusion weighted imaging (DWI) and fluid‐attenuated inversion recovery (FLAIR). After two courses of intravenous methylprednisolone, clinical symptoms improved, but the corpus callosum lesion remained. Antiglial fibrillary acidic protein (GFAP) antibodies were detected, confirming the diagnosis of GFAP astrocytopathy (GFAP‐A). This case highlights persistent corpus callosum lesions that develop early as a potential radiological feature of GFAP‐A, despite the absence of linear perivascular radial enhancement.
- 11 July 2025
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 13 (5) , 369-371
A Case of Autoimmune Glial Fibrillary Acid Protein Astrocytopathy Presenting an Irreversible Lesion in the Corpus Callosum
A 22‐year‐old female patient displayed fevers, headaches, and disturbed consciousness. A brain MRI demonstrated hyperintensity in the splenium of the corpus callosum with diffusion weighted imaging (DWI) and fluid‐attenuated inversion recovery (FLAIR). After two courses of intravenous methylprednisolone, clinical symptoms improved, but the corpus callosum lesion remained. Antiglial fibrillary acidic protein (GFAP) antibodies were detected, confirming the diagnosis of GFAP astrocytopathy (GFAP‐A). This case highlights persistent corpus callosum lesions that develop early as a potential radiological feature of GFAP‐A, despite the absence of linear perivascular radial enhancement.
- 17 October 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 11 (1) , 58-60
Novel ABCD1 mutation detected in a symptomatic female carrier of adrenoleukodystrophy
We report a case of a symptomatic female carrier of X‐linked adrenoleukodystrophy (ALD) with a novel ABCD1 gene mutation. She has developed slowly progressive gait disturbance since age 40, and her father and sister had similar symptoms. When admitted to our hospital at age 66, blood analysis showed slight increase of very long‐chain fatty acids (VLCFA), and DNA analysis of ABCD1 gene revealed a novel heterozygous missense mutation (c.1700 A>C, p.Gln567Pro). The genetic testing for ABCD1 gene can be considered in female patients over middle age presenting spastic gait, because female ALD carriers tend to be symptomatic beyond age 60.
- 17 October 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 11 (1) , 58-60
Novel ABCD1 mutation detected in a symptomatic female carrier of adrenoleukodystrophy
We report a case of a symptomatic female carrier of X‐linked adrenoleukodystrophy (ALD) with a novel ABCD1 gene mutation. She has developed slowly progressive gait disturbance since age 40, and her father and sister had similar symptoms. When admitted to our hospital at age 66, blood analysis showed slight increase of very long‐chain fatty acids (VLCFA), and DNA analysis of ABCD1 gene revealed a novel heterozygous missense mutation (c.1700 A>C, p.Gln567Pro). The genetic testing for ABCD1 gene can be considered in female patients over middle age presenting spastic gait, because female ALD carriers tend to be symptomatic beyond age 60.
- 1 September 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 252-254
A case of successful renal transplantation of Charcot-Marie-Tooth disease associated with FSGS due to mutation of the INF2 gene
- 1 September 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 252-254
A case of successful renal transplantation of Charcot-Marie-Tooth disease associated with FSGS due to mutation of the INF2 gene
- 22 August 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 266-268
Japanese case of Charcot–Marie–Tooth disease type 2Z with severe retinitis pigmentosa
- 22 August 2022
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 10 (5) , 266-268
Japanese case of Charcot–Marie–Tooth disease type 2Z with severe retinitis pigmentosa
- Open Access
- 26 March 2022
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 61 (21) , 3217-3223
Drastic Improvement in Hepatitis B/C Virus-induced Decompensated Liver Cirrhosis Treated by Total Management Consisting of Interventional Radiology, Endoscopy, and Pharmacotherapy
Recent advances in antiviral therapy have enabled control of the hepatitis virus; however, these do not completely eliminate the pathological condition of liver disease, and portal hypertension remains a clinical problem. We herein report a case of hepatitis B virus/hepatitis C virus (HBV/HCV)-induced decompensated liver cirrhosis for which total management consisting of interventional radiology and endoscopy, based on the evidence of our clinical studies, followed by antiviral therapy for co-infection with HBV and HCV was successful. This case clearly indicates the effective timing of total management, suggesting that it prolongs the vital prognosis in addition to improving the hepatic function.
- 26 March 2022
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 61 (21) , 3217-3223
Open AccessDrastic Improvement in Hepatitis B/C Virus-induced Decompensated Liver Cirrhosis Treated by Total Management Consisting of Interventional Radiology, Endoscopy, and Pharmacotherapy
Recent advances in antiviral therapy have enabled control of the hepatitis virus; however, these do not completely eliminate the pathological condition of liver disease, and portal hypertension remains a clinical problem. We herein report a case of hepatitis B virus/hepatitis C virus (HBV/HCV)-induced decompensated liver cirrhosis for which total management consisting of interventional radiology and endoscopy, based on the evidence of our clinical studies, followed by antiviral therapy for co-infection with HBV and HCV was successful. This case clearly indicates the effective timing of total management, suggesting that it prolongs the vital prognosis in addition to improving the hepatic function.
- 17 August 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 9 (6) , 470-473
A case of rheumatoid meningoencephalitis induced by pembrolizumab
- 17 August 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 9 (6) , 470-473
A case of rheumatoid meningoencephalitis induced by pembrolizumab
- 27 May 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 9 (4) , 346-348
The first case of chronic inflammatory demyelinating polyneuropathy after transsexualism and continuous testosterone administration
- 27 May 2021
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 9 (4) , 346-348
The first case of chronic inflammatory demyelinating polyneuropathy after transsexualism and continuous testosterone administration